Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment. [PDF]
Lavoie G +11 more
europepmc +1 more source
Early and Sustained Clinical Benefits of Benralizumab in Severe Eosinophilic Asthma: Findings from the ORBE II Study. [PDF]
Ausín P +8 more
europepmc +1 more source
Longitudinal multi-trajectory phenotypes of severe eosinophilic asthma on type 2 biologics treatment. [PDF]
Pham DD +28 more
europepmc +1 more source
The Effect of Mepolizumab on Blood Eosinophil Subtype Distribution and Granule Protein Gene Expression in Severe Eosinophilic Asthma. [PDF]
Rimkunas A +6 more
europepmc +1 more source
Effect of the Arg16Gly β<sub>2</sub>-Adrenergic Receptor Polymorphism on Long-Term Mepolizumab Response and Clinical Remission in Severe Eosinophilic Asthma: A Genotype-Stratified, Multicenter Study. [PDF]
Nolasco S +19 more
europepmc +1 more source
Consensus from European experts on severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: Results from the OverSEA Delphi study. [PDF]
Bachert C +10 more
europepmc +1 more source
Biomarkers for Severe Eosinophilic Asthma [PDF]
The last decade has seen the approval of several new biologics for the treatment of severe asthma-targeting specific endotypes and phenotypes. This review will examine how evidence generated from the mepolizumab clinical development program showed that blood eosinophil counts, rather than sputum or tissue eosinophil counts, evolved as a pharmacodynamic
Frank Albers +2 more
exaly +6 more sources
Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma [PDF]
Some patients with severe asthma have frequent exacerbations associated with persistent eosinophilic inflammation despite continuous treatment with high-dose inhaled glucocorticoids with or without oral glucocorticoids.In this randomized, double-blind, double-dummy study, we assigned 576 patients with recurrent asthma exacerbations and evidence of ...
Guy Brusselle +2 more
exaly +5 more sources
Related searches:
Clusters of Severe Eosinophilic Asthma in a Korean Asthma Cohort
Respiration, 2021<b><i>Background:</i></b> Targeted therapies have broadened the available treatment options for patients with severe eosinophilic asthma (SEA). However, differences in the magnitude of treatment responses among patients indicate the presence of various underlying pathophysiological processes and patient subgroups. <b><i&
Ji-Hyang Lee +25 more
openaire +2 more sources

